HeartSciences reports Q1 FY2025 cash of $4.3M, raises $1.9M in non-dilutive debt; MyoVista device on track

HeartSciences Inc.

Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.
Subsequent to quarter end, closed $1.9M net non-dilutive 18-month loan and extended $500K loan to Sep 2025.
FDA 510(k) submission for MyoVista wavECG device remains on track for Q1 calendar 2025.
Cloud-based MyoVista Insights platform Phase 1 on track for end of calendar 2024; FDA submission target H2 2025.
No revenue reported for Q1 FY2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.